By: Michael Flanagan
Despite having already rejected Replimmune's oncolytic immunotherapy twice, the FDA reversed course — perhaps swayed by a positive adcom vote last
United States (National)
Geo Focus
Coverage Attributes:
Beta
Informative:
40
%
Interviews Q&as:
29
%
Data Driven:
14
%
Events:
10
%
Opinion:
4
%
Themes Covered:
Not enough data
Pitching Insights
Michael Flanagan's coverage primarily focuses on house & home topics, with occasional articles relating to food & beverage. While there is a diversity of themes covered, the majority of his articles are "How To Guide" and data-driven pieces.
For successful pitching, consider providing content related to innovative or transformative trends in house & home sector and data-backed insights into food & beverage industry. Additionally, any contributions should align with Michael's focus on practical guides or data-driven analysis.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
